Smit EF - Search Results

1

de Ruiter JC, Smit EF, van der Noort V, Hartemink KJ. de Ruiter JC, et al. Among authors: smit ef. Eur J Cardiothorac Surg. 2022 Jun 15;62(1):ezac310. doi: 10.1093/ejcts/ezac310. Eur J Cardiothorac Surg. 2022. PMID: 35640126 No abstract available.

2

Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer.

Phernambucq EC, Spoelstra FO, Paul MA, Senan S, Melissant CF, Postmus PE, Smit EF. Phernambucq EC, et al. Among authors: smit ef. Eur J Cardiothorac Surg. 2009 Dec;36(6):1052-7. doi: 10.1016/j.ejcts.2009.05.025. Epub 2009 Jul 17. Eur J Cardiothorac Surg. 2009. PMID: 19616442

3

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.

Lind JS, Postmus PE, Heideman DA, Thunnissen EB, Bekers O, Smit EF. Lind JS, et al. Among authors: smit ef. J Thorac Oncol. 2009 Dec;4(12):1585-6. doi: 10.1097/JTO.0b013e3181bbb2b9. J Thorac Oncol. 2009. PMID: 20009914 Free article.

4

Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.

Lind JS, Postmus PE, Smit EF. Lind JS, et al. Among authors: smit ef. J Thorac Oncol. 2010 Apr;5(4):554-7. doi: 10.1097/JTO.0b013e3181d3e47e. J Thorac Oncol. 2010. PMID: 20357621 Free article.

5

Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.

Phernambucq EC, Hartemink KJ, Smit EF, Paul MA, Postmus PE, Comans EF, Senan S. Phernambucq EC, et al. Among authors: smit ef. J Thorac Oncol. 2012 Aug;7(8):1271-5. doi: 10.1097/JTO.0b013e3182582912. J Thorac Oncol. 2012. PMID: 22659960 Free article.

6

Benefit of a second opinion for lung cancer: no recurrent disease, but infection.

Schook RM, Smit EF, Postmus PE, Hartemink KJ, Paul MA. Schook RM, et al. Among authors: smit ef. J Thorac Oncol. 2012 Aug;7(8):e6-7. doi: 10.1097/JTO.0b013e31825cca93. J Thorac Oncol. 2012. PMID: 22797154 Free article. No abstract available.

7

Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol.

Vos CG, Hartemink KJ, Blaauwgeers JL, Oosterhuis JW, Senan S, Smit EF, Thunnissen E, Paul MA. Vos CG, et al. Among authors: smit ef. Eur J Surg Oncol. 2013 Feb;39(2):197-203. doi: 10.1016/j.ejso.2012.09.002. Epub 2012 Oct 11. Eur J Surg Oncol. 2013. PMID: 23062624

8

[Treatment and prognosis of superior sulcus tumours].

Vos CG, Dickhoff C, Paul MA, Dahele M, Smit EF, Hartemink KJ. Vos CG, et al. Among authors: smit ef. Ned Tijdschr Geneeskd. 2012;156(49):A5419. Ned Tijdschr Geneeskd. 2012. PMID: 23218036 Review. Dutch.

9

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.

Blaauwgeers JL, Kappers I, Klomp HM, Belderbos JS, Dijksman LM, Smit EF, Postmus PE, Paul MA, Oosterhuis JW, Hartemink KJ, Vos CG, Burgers JA, Dahele M, Phernambucq EC, Witte BI, Thunnissen E. Blaauwgeers JL, et al. Among authors: smit ef. Virchows Arch. 2013 May;462(5):547-56. doi: 10.1007/s00428-013-1404-6. Epub 2013 Apr 3. Virchows Arch. 2013. PMID: 23549732

10

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.

Mellema WW, Dingemans AM, Thunnissen E, Snijders PJ, Derks J, Heideman DA, Van Suylen R, Smit EF. Mellema WW, et al. Among authors: smit ef. J Thorac Oncol. 2013 Sep;8(9):1190-5. doi: 10.1097/JTO.0b013e318298764e. J Thorac Oncol. 2013. PMID: 23787801 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

515 results

Search Page